Here we report the synthesis and in vivo performance of [111In]XYIMSR-01, a modified dual-motif CAIX inhibitor with improved tumor uptake and pharmacokinetics for nuclear imaging of ccRCC. This evidence concerns the gene CA9 and nonpapillary renal cell carcinoma.